Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Mature
Primary summary from verified readiness
- Confidence
- 59% · fresh
- Computed at
- 2026-07-21T07:34:41.007559+00:00
- Claimed
- 92
- Reported
- 88
- Verified
- 78
- Gap
- +14
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Critical
Decision
What the current evidence supports
Human editorial judgment · 2026-07-21
Track; not yet
- Why
- FDA-approved with strong Phase 3 efficacy (56-59% LDL-C reduction vs placebo, first-in-class oral PCSK9 mechanism, priced ~37-47% below injectables) and genuinely category-defining, but insurer coverage and actual real-world uptake remain unresolved variables — the registry should wait for post-launch adoption signal rather than treat this as a settled shift while it is still pre-commercial.
- Next
- Revisit after U.S. commercial launch (expected within a few weeks of the 2026-07-16 approval) once payer coverage decisions and real-world prescribing volume are reported — recheck by Q4 2026.
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 4
- Tier 1
- 0
- Tier 2
- 2
- Tier 3
- 2
- Supports
- 3
- Contradicts
- 1
- Context
- 0
- Latest observed
- 2026-07-16
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-07-21 Reading moved from mature to mature.